PDCD1 and prostate carcinoma: Martini et al.'s clinical research on prostate cancer demonstrated that the survival advantage of TYG might partly be attributed to the downregulation of certain oncogenes and/or the upregulation of programmed cell death protein 1 (PD‐1) expression determined by the immunosuppressive effect of obesity, ultimately leading to greater susceptibility to PD‐1 inhibitors.22